Spondyloarthritis

Korean National Insurance claims study (2010–2023) of treatment persistence of IL-17i vs TNFi (IL-17i: 375; TNFi: 1285) in 1660 axSpA pts found equal Tx durations. However, primary nonresponse D/C was significantly higher w/ TNFi vs IL-17i (adj HR 1.54 to 2.11) https://t.co/2CF4OCPT6z
Dr. John Cush @RheumNow( View Tweet )
Annual fibromyalgia survey (FIRST) in axSpA pts in the DESIR cohort. FM was found in 22% (& assoc w/ less HLA-B27+ & XRay sacroiliitis, equal MRI SI a& ^ CRP. FM/AxSpA had less self-reported Dz activity, QOL, more disability & more likely to Rx w/ TNFi (64% vs 41%), but resp https://t.co/Rf5RGIanAP
Dr. John Cush @RheumNow( View Tweet )
FDA%20approved.jpg (keep)

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2)
Read Article
RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
Retrospective study of 1553 IBD pts taking biologics or JAKi, w/ 5+ yrs of F/U, 6.8% developed MSK Sxs, with one-third subsequently Dx w/ SpA. HLA-B27 positivity (HR 3.7) and higher UC disease activity (HR 1.57) were associated with an increased risk of SpA. https://t.co/I2YSOLhkAb
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

SATISFACTION (2.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Sonelokimab (SLK) is a nanobody that inhibits IL-17A & IL-17F. Press release from Moonlake shows SLK was effective in the phase 2, S-OLARIS study of 26 axial spondyloarthritis pts where 80+% of patients achieved ASAS40 by Week 12 https://t.co/BQjBcvESfe https://t.co/tXRKj8CPbz

Links:

Dr. John Cush @RheumNow( View Tweet )
Peripheral manifestations are inconsistently assessed in axSpA trials. b/tsDMARDs have small-to-mod effects on peripheral Sxs & may be underestimated. Assessments in axSpA RCTs were low for periph arthritis 54%, enthesitis in 64% and dactylitis in only 10% of studies. https://t.co/cCNvU1oZMh
Dr. John Cush @RheumNow( View Tweet )
What's New in Spondyloarthritis Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in axial spondyloarthritis (axSpA) at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. https://t.co/X9MfrZLNBq https://t.co/VS04Ra5RZK

Links:

Dr. John Cush @RheumNow( View Tweet )
J Rheum full read editorial on What HLA-B27 Can—and Cannot—Tell Us!. HLA-B27 also holds prognostic and theragnostic value, given its association with greater structural damage, higher inflammatory burden, and better response to tumor necrosis factor and interleukin 17 inhib. https://t.co/3xNDtePEzn
Dr. John Cush @RheumNow( View Tweet )
AS.Sacroiliitis.CT_.SpA_.jpg

What's New in Spondyloarthritis

Robert Chao, MD

Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in spondyloarthritis at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. Here's a summary.

Read Article
RT @ericdeinMD #RNL26 Arthroplasty risks in RMD AxSpA - Respiratory complications (OR 1.7), PNA (2.2) SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush @RheumNow( View Tweet )
RNL 26 Report: Spondyloarthritis Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session. https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD

Links:

Dr. John Cush @RheumNow( View Tweet )
Staying Ahead of Spondyloarthritis The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis." https://t.co/hZeqYC7wi3 https://t.co/2eKEueAukY

Links:

Dr. John Cush @RheumNow( View Tweet )
Bakewell Walsh Poddubnyy panel

Staying Ahead of Spondyloarthritis

Eric Dein, MD

The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis", which reviewed diagnosis, complications and advances in SpA.

Read Article
research2.jpg

Canada's 2025 Top 10 Funded Rheumatology Projects

Arthritis Society

Arthritis Society Canada (ASC) is Canada’s largest charitable funder of cutting-edge arthritis research, investing more than $240 million in research projects since its founding, and over $7 million invested in 2024-2025. Below are the investigators and projects that were funded in 2025.

Read Article
RNL, over, microphone

RheumNow Live Preview (1.30.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.

Read Article
2026 SPARTAN Annual Meeting (May 14-16; Toronto) is now accepting abstract submissions! A premier mtg brings together cutting-edge researchers and teachers in spondyloarthritis (SpA). Submit your abstracts by Feb 1st!! https://t.co/IBXEkSxpDy https://t.co/cS7exDUc9H

Links:

Dr. John Cush @RheumNow( View Tweet )
Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
2025

The 2025 Rheumatology Year in Review

Jack Cush, MD

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

2026 Resolutions (1.9.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/fxFcqy13g7
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” https://t.co/hFejdS4sjk
Dr. John Cush @RheumNow( View Tweet )

Therapeutic Updates

5-Year Results of an IL-23 Inhibitor in Patients With PsA

AbbVie March 2026
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post

Recent Blogs

Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics.
Read Post

A Domain-Based Approach to the GRAPPA Psoriatic Arthritis Treatment Recommendations

Laura Coates
heel enthesitis spur calcaneal

With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.

Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 SpA Topic Podcasts Compilation 2
  • ACR 2025 Daily Podcasts Day4b
  • ACR 2025 Daily Podcasts Day4a
×